The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

The price negotiation process was established under former President Joe Biden's signature Inflation Reduction Act in 2022.

The U.S. government said on Wednesday it will aim for "greater transparency" in Medicare drug price negotiations under ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Novo Nordisk's blockbuster drug is now a kidney disease fighter, threatening dialysis giants and reshaping the ...

The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...

The FDA on Tuesday approves Ozempic, the weight loss drug made by Novo Nordisk, for the treatment of chronic kidney disease ...

Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

RFK Jr. directly addressed to the Senate Finance Committee that he is not anti-vaccine during his opening statement for his ...